Press & media
Press & media
Everything a journalist needs to describe Vanguard Biotech Systems and NextGenAMR accurately, drawn from approved statements. For interviews, materials or clarifications, use the press contact below.
Please note when writing about NextGenAMR
To describe the product accurately, please do NOT present NextGenAMR as any of the following:
- NextGenAMR is not presented as an autonomous diagnostic system; it organises genomic evidence and generates outputs for professional review.
- NextGenAMR does not replace phenotypic antimicrobial susceptibility testing (AST). Genomic outputs must be interpreted together with AST, microbiological context and applicable procedures.
- NextGenAMR does not select treatments and does not generate autonomous therapeutic recommendations. Clinical decisions remain with qualified professionals.
Corporate boilerplate
Vanguard Biotech Systems is a Spanish biotechnology software company developing genomic intelligence systems for antimicrobial resistance. It is a founder-led company incorporated as a Sociedad de Responsabilidad Limitada (S.L.) in 2025, with its operational base in Granada and its registered office in Lepe, Huelva. NextGenAMR is the first product developed by Vanguard Biotech Systems. Juan Manuel Gómez Vargas — Founder & CEO of Vanguard Biotech Systems.
About the company
Vanguard Biotech Systems is a Spanish biotechnology software company developing genomic intelligence systems for antimicrobial resistance. It is a founder-led company incorporated as a Sociedad de Responsabilidad Limitada (S.L.) in 2025, with its operational base in Granada and its registered office in Lepe, Huelva.
About the company →About NextGenAMR
NextGenAMR is the first product developed by Vanguard Biotech Systems. Vanguard Biotech Systems develops NextGenAMR, a bioinformatics software platform that processes supported cultured-isolate WGS inputs within its published scope, organises genomic evidence related to antimicrobial resistance, preserves run-level provenance and generates outputs for professional review. NextGenAMR is in controlled preview, with internal non-clinical testing in progress and an independent validation programme in preparation; no independent performance results are published. It is not presented as an autonomous diagnostic system, a replacement for phenotypic AST or a tool that selects treatments.
NextGenAMR is a functional platform in controlled preview. Internal non-clinical testing is in progress and an independent validation programme is in preparation; no independent performance results are published. The product is not presented as an autonomous diagnostic or treatment-decision system.
Company facts
- Founded
- Founded in 2025 in Granada, Spain.
- Location
- Granada, Spain
- Founder & CEO
- Juan Manuel Gómez Vargas — Founder & CEO of Vanguard Biotech Systems.
- First product
- NextGenAMR is the first product developed by Vanguard Biotech Systems.
Media assets
Logos, authorised photographs and additional materials are available on request through the press contact. We do not publish brand assets or internal materials without authorisation.
Press contact
Write to us through the contact form and select “Press”. We reply according to the request.